Luye Pharma Group (LYPHF) AI Stock Analysis

• Market Cap: $1.38B
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): 15.4
• Beta (1Y): 0.45
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5,150
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - General
• EPS (TTM): <0.01
• Shares Outstanding: 3,761,670,700
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: -0.36
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $0.35
• Price Target Upside: 29.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Luye Pharma Group Business Overview & Revenue Model

Company Description

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

How the Company Makes Money

Luye Pharma Group Financial Statement Overview

Summary

Luye Pharma Group demonstrates strong profitability with healthy EBIT and EBITDA margins. The balance sheet is solid with a moderate debt-to-equity ratio, but cash flow stability is a concern due to inconsistent free cash flow growth. Overall, the financial structure is robust, though sustaining growth momentum is challenging.

Income Statement

Luye Pharma Group shows robust gross and net profit margins, indicating efficient cost management and profitability. However, the revenue growth has been inconsistent, showing a decline in the most recent year. EBIT and EBITDA margins are healthy, reflecting strong operational performance.

Balance Sheet

The company maintains a moderate debt-to-equity ratio, suggesting a balanced approach to leveraging. ROE is relatively stable, indicating effective utilization of equity. The equity ratio signifies a solid capital structure, though there is room for improvement in reducing debt levels.

Cash Flow

Cash flow stability is a concern, with inconsistent free cash flow growth and operating cash flow to net income ratios. However, the company has managed to maintain positive cash flow from operations in recent years, indicating operational efficiency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
6.06B	6.14B	5.98B	5.20B	5.54B
	Gross Profit
4.04B	4.20B	4.14B	3.40B	3.99B
	EBIT
1.15B	887.44M	1.21B	386.99M	1.42B
	EBITDA
1.79B	2.08B	1.81B	906.88M	1.88B
	Net Income Common Stockholders
471.89M	532.61M	604.81M	-144.78M	706.59M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.50B	6.11B	5.54B	5.51B	5.41B
	Total Assets
29.61B	25.49B	24.25B	22.58B	20.63B
	Total Debt
10.32B	8.42B	9.10B	9.49B	9.98B
	Net Debt
5.38B	5.18B	6.78B	7.05B	6.12B
	Total Liabilities
13.86B	11.96B	13.21B	13.47B	12.53B
	Stockholders Equity
14.15B	12.53B	10.18B	8.49B	7.89B
Cash Flow		Free Cash Flow
0.00	430.23M	490.14M	-1.36B	-486.43M
	Operating Cash Flow
0.00	1.60B	1.65B	182.37M	1.03B
	Investing Cash Flow
0.00	-1.42B	-1.66B	-3.44B	138.20M
	Financing Cash Flow
0.00	841.60M	54.15M	1.88B	253.98M

Luye Pharma Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYPHF		$1.38B	15.40	3.53%	―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
CHJTF		$12.98B	16.93	13.20%	4.42%	―	―
SHPHF		$1.22B	―	-4.93%	2.69%	―	―
C1P		€1.08B	7.72	23.28%	6.45%	―	―
6826	68 Neutral	HK$11.93B	13.69	7.25%	4.65%	-1.81%	-3.79%
1558	66 Neutral	HK$11.49B	21.98	5.88%	―	-42.02%	-76.29%